Cytora

Oral Mucosa Stem Cell Therapy

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in April 2015 by Jacob Zankel and Prof. Sandu Pitaru, Cytora operates with 11–50 employees. The company has raised $2 million across two funding rounds from Net Capital Ventures and G.O Innovation. In May 2026, Cytora appointed Dr. Thomas Serena, a renowned wound care expert, to its Scientific Advisory Board to advance patient treatment access and data collection for its hOMSC therapy.

Business overview

Cytora is a clinical-stage biotechnology company focused on developing allogeneic stem cell therapies derived from human oral mucosa stem cells (hOMSC). The company aims to establish hOMSC as a standard treatment for severe diseases, including Parkinson’s, Multiple System Atrophy (MSA), Alzheimer’s Dementia, and non-healing diabetic wounds. Operating within the Health Tech & Life Sciences sector, Cytora’s core technology leverages biological cells to address critical unmet medical needs in pharmaceuticals and life sciences.

Strategic signal

In May 2026, Cytora appointed Dr. Thomas Serena, a world-renowned wound care expert, to its Scientific Advisory Board. This strategic addition signals Cytora's commitment to advancing its hOMSC therapy by leveraging top-tier expertise for patient treatment access and data collection, indicating a strong focus on clinical development and market penetration for its stem cell treatments.

Log in to access full profile

Company Intelligence Q&A

What is Cytora's primary focus?
Cytora is a clinical-stage biotechnology company developing allogeneic stem cell therapies from human oral mucosa stem cells (hOMSC) for treating severe diseases such as Parkinson’s, Alzheimer’s Dementia, and non-healing diabetic wounds.
When was Cytora founded and by whom?
Cytora was founded in April 2015 by Jacob Zankel and Prof. Sandu Pitaru.
What significant appointment did Cytora make in May 2026?
In May 2026, Cytora appointed Dr. Thomas Serena, a world-renowned wound care expert, to its Scientific Advisory Board to lead patient treatment access and data collection for its hOMSC therapy.
What were the results of Cytora's Phase 1/2a trial for diabetic foot ulcers?
In April 2025, Cytora reported successful results from its Phase 1/2a trial of stem cell treatment for diabetic foot ulcers.
Log in to access full profile